China's National Health Commission, National Healthcare Security Administration,
National Administration of Traditional Chinese Medicine and the CDC on the 10th
issued a notice to further improve safe, rational allocation and use of
innovative drugs, focusing on promoting rational allocation, strengthening
training and guidance, easing use conditions and improving management. The
notice directs implementation of pharmacy-related medical service pricing items,
pledges enhanced support measures to optimize the policy environment for
innovative drugs, states medical institutions will not be restricted on total
drug varieties/specifications, and clarifies relevant innovative drugs will be
excluded from public hospitals' performance-monitoring indicators, including
outpatient and inpatient per‑visit drug-cost growth.
